Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Primary Breast Cancer
Interventions
DRUG

Epirubicin, Carboplatin, Docetaxel

75 mg/m² Docetaxel (60 minutes i.v.) and 90 mg/m² Epirubicin (10-15 min i.v.) on day 1, 22, 42. After these 3 cycles 75 mg/m² Docetaxel (60 minutes i.v.) and Carboplatin AUC 5 (30 min i. v.) on day 63, 84, 105.

Trial Locations (3)

39110

Klinikum Marienstift, Magdeburg

06110

Krankenhaus St. Elisabeth u. St. Barbara, Halle

06667

Asklepios Krankenhaus Weissenfels, Weißenfels

All Listed Sponsors
lead

Klinikum Weissenfels

OTHER

NCT00527449 - Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel | Biotech Hunter | Biotech Hunter